EUVIMEDEUVIMED entdecken
Kohortenstudie

Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study

Emre Akar, Şüheda Çakmak, Mehmet Baysal, Seval Akpınar, Burhan Turgut

Indian Journal of Hematology and Blood Transfusion · 29.06.2026

DOI: 10.1007/s12288-026-02460-1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 29.06.2026. Verfasst von Emre Akar und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) negativity is a validated prognostic marker in multiple myeloma, though most evidence derives from clinical trials using highly sensitive platforms not routinely available worldwide. Real-world data on conventional multiparametric flow cytometry (MFC)-based MRD assessment remain limited. This retrospective single-center study included 91 newly-diagnosed multiple myeloma patients. MRD was assessed by MFC at 10⁻⁴ sensitivity using an 8-color antibody panel after first-line therapy and two months post-autologous stem cell transplantation(ASCT) in patients achieving very good partial response or better. Bone marrow samples with minimum 500,000 acquired events were analyzed. Survival outcomes were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Among 70 patients evaluated pre-transplant, 55.7% were MRD-negative. Post-ASCT, 58.1% of 62 transplanted patients achieved MRD negativity. Pre-transplant MRD status showed a non-significant trend toward longer progression-free survival (PFS) (42.3 vs. 31.5 months, p = 0.0609). Post-ASCT MRD positivity was significantly associated with worse outcomes: median overall survival (OS) was 48.3 versus 89.6 months ( p = 0.0065) and median PFS was 26.4 versus 51.7 months ( p = 0.0091) in MRD-positive versus MRD-negative patients, respectively. The overall cohort median OS was 72.3 months and median PFS was 38.6 months. MFC-based MRD assessment at 10⁻⁴ sensitivity demonstrated significant prognostic value in the post-ASCT setting within a real-world cohort, despite treatment heterogeneity and limited sample size. These findings support the clinical utility of accessible MRD assays in resource-limited settings and highlight the need for standardized, broadly implementable MRD assessment strategies to guide treatment decisions and improve global patient outcomes.

Zitieren

APA

Akar, E., Çakmak, Ş., Baysal, M., Akpınar, S., & Turgut, B. (2026). Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study. Indian Journal of Hematology and Blood Transfusion. https://doi.org/10.1007/s12288-026-02460-1

Vancouver

Akar E, Çakmak Ş, Baysal M, Akpınar S, Turgut B. Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study. Indian Journal of Hematology and Blood Transfusion. 2026. doi:10.1007/s12288-026-02460-1

BibTeX
@article{Akar2026,
  author = {Akar, Emre and Çakmak, Şüheda and Baysal, Mehmet and Akpınar, Seval and Turgut, Burhan},
  title = {Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study},
  journal = {Indian Journal of Hematology and Blood Transfusion},
  year = {2026},
  doi = {10.1007/s12288-026-02460-1}
}
Kostenlos starten →